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Factors accounting for long-term nonprogression may include infection with an attenuated strain of human
immunodeficiency virus type 1 (HIV-1), genetic polymorphisms in the host, and virus-specific immune re-
sponses. In this study, we examined eight individuals with nonprogressing or slowly progressing HIV-1 infec-
tion, none of whom were homozygous for host-specific polymorphisms (CCR5-D32, CCR2-64I, and SDF-1-3*A)
which have been associated with slower disease progression. HIV-1 was recovered from seven of the eight, and re-
covered virus was used for sequencing the full-length HIV-1 genome; full-length HIV-1 genome sequences from
the eighth were determined following amplification of viral sequences directly from peripheral blood mono-
nuclear cells (PBMC). Longitudinal studies of one individual with HIV-1 that consistently exhibited a slow/low
growth phenotype revealed a single amino acid deletion in a conserved region of the gp41 transmembrane pro-
tein that was not seen in any of 131 envelope sequences in the Los Alamos HIV-1 sequence database. Genetic
analysis also revealed that five of the eight individuals harbored HIV-1 with unusual 1- or 2-amino-acid dele-
tions in the Gag sequence compared to subgroup B Gag consensus sequences. These deletions in Gag have ei-
ther never been observed previously or are extremely rare in the database. Three individuals had deletions in Nef,
and one had a 4-amino-acid insertion in Vpu. The unusual polymorphisms in Gag, Env, and Nef described here
were also found in stored PBMC samples taken 3 to 11 years prior to, or in one case 4 years subsequent to, the
time of sampling for the original sequencing. In all, seven of the eight individuals exhibited one or more unusual
polymorphisms; a total of 13 unusual polymorphisms were documented in these seven individuals. These poly-
morphisms may have been present from the time of initial infection or may have appeared in response to im-
mune surveillance or other selective pressures. Our results indicate that unusual, difficult-to-revert polymor-
phisms in HIV-1 can be found associated with slow progression or nonprogression in a majority of such cases.
Disease induction following human immunodeficiency virus
type 1 (HIV-1) infection, or the ability to control the infection
in rare cases, is likely to be regulated by the balance of at least
three factors: genetic susceptibility of the host, the ability of
the host to elicit effective immune responses, and the sequence
of the incoming virus.
Twenty-five to 30% of long-term nonprogressors (LTNPs)
who have remained AIDS free for more than 15 years in the
absence of antiretroviral drugs express specific mutant forms of
the HIV-1 second receptors CCR5 and CCR2 (11, 23, 52).
Individuals who are homozygous for a 32-bp deletion (D32) in
CCR5, which encodes the most frequently used second re-
ceptor for HIV-1, are resistant to infection by HIV-1 (11, 36).
HIV-1-infected individuals who are heterozygous for CCR5D32
(2/1) show a slightly slower disease progression than CCR51/1
homozygotes (11, 23, 36, 49). A V64I polymorphism in the
CCR2 gene, which is linked to a point mutation in the regula-
tory region of the CCR5 gene, and a common polymorphism in
the 39-untranslated region of the stromal derived factor gene
(SDF-1) are also associated with delayed disease progression
(3, 5, 6, 57). SDF-1 is the natural ligand for CXCR4, the sec-
ond receptor for syncytium-inducing strains of HIV-1. Intra-
cellular factors may also contribute to the inherent suscepti-
bility of host cells to support HIV replication (13, 22, 35).
HIV-1-infected individuals who are LTNPs also appear in
general to have more effective HIV-1-specific immune re-
sponses. Perhaps most remarkable is the HIV-specific CD4
helper cell activity seen in nonprogressors controlling their
HIV infection (47). This vigorous helper cell response con-
trasts with the absent or low response typically observed in
progressors (47). Nonprogressors also generally exhibit more
vigorous cytotoxic T-lymphocyte (CTL) activity than typical
progressors (18, 21). The ability to mount effective immune
responses may be influenced by the extent of heterozygosity at
major histocompatibility complex class I (MHC-I) loci or by
the specific MHC-I genotype or both (6). The ability to mount
effective immune responses may of course be related in some
cases to the virulence of the infecting strain of HIV-1 and/or
the inherent susceptibility of the host.
One patient from central Massachusetts (27) and nine from
Australia (10) are infected with Nef-deleted forms of HIV-1.
* Corresponding author. Mailing address: Harvard Medical School,
New England Regional Primate Research Center, 1 Pine Hill Dr.,
Southborough, MA 01772-9102. Phone: (508) 624-8002. Fax: (508)
460-0612. E-mail: ronald_desrosiers@hms.harvard.edu.
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Infection with this replication-competent, attenuated form of
HIV-1 is clearly responsible for slow progression or nonpro-
gression in these individuals (10, 27). This is particularly evi-
dent for eight of the individuals in the Australian cohort, who
were all infected by a single blood donor, who all have the
Nef-defective form of the virus, and who all have been slow
progressors or nonprogressors (33, 43). An additional LTNP
with consistently deficient forms of Nef has been described
(48). One LTNP whose rev gene exhibited deficient activity
over more than 4.5 years of observation has been described
(25), another with a consistently defective p17 sequence (5)
and a nonprogressing infant-mother pair containing defects
clustered in the C terminus of Vpr have been documented
(54).
In this report we describe full-length HIV-1 sequences from
eight nonprogressors living in New England. Additional exam-
ples of uniform, nonrevertible inactivating deletions in auxil-
iary genes were not discovered. However, unusual, difficult-to-
revert polymorphisms were noted in the HIV-1 present in
seven of these eight individuals.
MATERIALS AND METHODS
LTNP HIV-1 cultures. Peripheral blood mononuclear cells (PBMC; 5 3 106)
from LTNPs were cocultivated with an equal number of phytohemagglutinin-
activated PBMC from seronegative donors. These cultures were monitored for
p24 production using an HIV-1 core antigen kit (Coulter, Hialeah, Fla.). If
HIV-1 replication was not detected in these cultures, CD8 cells were depleted
using immunomagnetic beads (Dynabeads; Dynal Inc, Great Neck, N.Y.) prior
to cocultivation (14). Using these protocols, HIV-1 was recovered from seven of
the eight LTNPs described in this report.
Isolation of cellular DNA. Infected cultured cells (5 3 106) or LTNP PBMC
were lysed in 0.5 ml of lysis buffer (10 mM Tris [pH 8.2], 0.4 M NaCl, 2 mM
EDTA [pH 8.2]) that was supplemented with 33 ml of 10% sodium dodecyl
sulfate (SDS) and 10 ml of proteinase K (10 mg/ml) for 1 h at 56°C. After lysis,
160 ml of saturated NaCl was added and the tube was inverted to mix the
reagents. The mixture was then centrifuged at 14,000 rpm in a microcentrifuge
for 10 min. The clear supernatant was removed and placed in a fresh tube, and
700 ml of isopropanol was added. The mixture was inverted and centrifuged for
10 min at 14,000 rpm. The supernatant was then removed, and the pellet was
washed with 70% ethanol and then air dried for 1 h.
Amplification of LTNP HIV-1 sequences. One microgram of cellular DNA
served as the template for PCR amplifications. Primers for PCR that annealed to
highly conserved regions of HIV-1 were chosen. These primers were designed
such that their sequences were rare in both the documented human genome and
HIV-1 sequences according to the Right Primer analysis program (Biodisk, San
Francisco, Calif.). In addition, they were designed to have annealing tempera-
tures of approximately 70°C as determined by the Oligo primer analysis program
(National Biosciences, Plymouth, Minn.). Stringent PCR conditions that had
been previously shown to optimize the amplification of large, low-copy-number
templates were chosen (3, 8, 58). A 200-ml reaction volume in a 0.5-ml thin-
walled PCR tube (Perkin-Elmer Cetus, Norwalk, Conn.) was used. The volume
included 2 U of rTthXL (Perkin-Elmer Cetus), 200 mM deoxynucleoside
triphosphates, and a 0.2 mM concentration of each primer. This PCR mixture
was preheated for 60 s at 80°C before 1.0 mM magnesium acetate was added.
The sample was then inserted into an Omnigene PCR cycler (Hybaid, Franklin,
Mass.) that was preheated to 80°C. Seventy-five cycles/round of PCR was used to
amplify LTNP HIV-1 sequences. Each cycle consisted of a 93°C denaturation
step followed by a rapid-cooling step to 70°C and a slow-cooling step to 65°C.
The 65°C annealing and polymerization step was carried out for 1 min for every
1 kbp of amplified HIV-1 sequence. The complete HIV-1 sequences from the
seven LTNPs for which virus was successfully isolated were obtained by ampli-
fication of 11 overlapping fragments of approximately 1 kbp each using a single
round of PCR for each fragment. HIV-1 from 161J has not been isolated, and
thus overlapping fragments of approximately 500 bp were amplified using two
rounds of PCR with nested primer sets to complete the HIV-1 sequences. Nested
PCR was also employed for amplification of HIV-1 sequences from PBMC
samples of LTNPs from whom virus was recovered. Overlapping PCR fragments
were treated with T4 DNA polymerase (New England Biolabs, Beverly, Mass.)
and inserted into a SmaI-digested pUC18 vector (Promega, Madison, Wis.). The
DNA sequence of the inserted fragment was then determined with M13 primers
using an ABI 377 DNA sequencer (Perkin-Elmer Cetus). Sequence data for
LTNP HIV-1 presented in this report represent a consensus of two independent
clones from each of two independent PCR amplifications. Nested PCR was used
to amplify HIV-1 DNA from the LTNP designated LTNP 5 and the infectious
clone NL 4-3 in two approximate halves which could be combined at a common
restriction site for transfection into cells. The internal oligonucleotide for the
amplification of each half genome contained an A-to-G change from the con-
sensus sequence which introduces an XmaI site (CCCGGG) into a highly con-
served region (nucleotide 4402 for NL 4-3) (1) without changing the pol amino
acid coding sequence. 59 PCR fragments included bp 297 to 4402, and 39 frag-
ments included bp 4402 to 9607 (base pairs are based on NL 4-3 sequences).
Phylogenetic analysis of LTNP sequences. The subtype of each LTNP HIV-1
sequence was determined by comparison to HIV-1 subtype reference sequences
using the Los Alamos subtyping program (B. Korber, www.ncbi.nih.gov, Los
Alamos National Laboratory, 1999). Phylogenetic trees based on neighbor-join-
ing analyses were produced to determine the genetic distance between LTNP
and reference gag and nef sequences using the PAUP phylogenetic analysis
software (D. L. Swofford, Phylogenetic analysis using parsimony [and other
methods], 4th ed., Sinauer Associates, Sunderland, Mass., 1998). The reference
sequences in these analyses, indicated by (in order) code, subgroup, strain,
identification number, and accession number(s) are as follows: A1A, U455,
328902, M230; A2, A, 92UG037.1, U51190; B1, B, OYI, 328440, M26727; B2, B,
RF, 328565, M17451, M12508, USA; C1, C, ETH2220, 1353860, U46016; C2, C,
92BR025.8, 2194183, U529523; D1, D, NDK, 328154, M27323; D2, D, Z2Z6,
329377, M22639; F1, F, 93BR020.1, 3114544, AF005494; H1, H, 90CR056.1,
3114562, AF005496; AEI, A/E (E in most of env, A in gag and pol, and a mixture
of A and E in regulatory genes), CM240, 1537050, U54771; G1, G, SE6165,
3403225, AF061642; E1, MP38; E2, MP59.
Plasmid construction. NL 4-3/LTNP Gag chimeras were engineered by inser-
tion of an ApaI-BclI-digested 320-base fragment that contained the coding se-
quence for LTNP p6gag-pol into ApaI-BclI-digested p83-2 plasmid which con-
tained NL 4-3 sequences. In order to engineer simian immunodeficiency virus/
HIVnef (SHIVnef) recombinants, SIVmac nef sequences were deleted from the
39 extent of the SIVmac env gene to 120 bases 59 of the NF-kB binding site in
SIVmac239 (45) and HIV-1 sequences derived from the LTNP 1486D were in-
serted as previously described (2). Thorough DNA sequence analysis verified
that all recombinant clones selected for study contained exactly the desired
sequences.
HIV-1 and SHIVnef replication assays. All stocks of NL 4-3 or recombinants
described in this report were generated by DEAE-dextran transfection of the cell
line CEMx174 (41). NL 4-3 or recombinant constructs were transfected into
CEMx174 cells, and virus in the cell-free supernatant was harvested at or near
the peak of virus production as previously described (15). Transfected or infected
CEMx174 cells were grown in RPMI 1640 (Gibco BRL, Grand Island, N.Y.) that
was supplemented with 10% fetal calf serum (Gibco BRL). The levels of p27 viral
protein that were produced from transfections or infections or that were con-
tained within viral stocks were quantified using a SIV core antigen kit (Coulter).
Analysis of Vpr incorporation. Virus from NL 4-3 or HIV-1Dvpr or recombi-
nants with LTNP p6gag sequences that contained 500 ng of p24 antigen were
centrifuged at 13,000 3 g for 2 h at 4°C. The supernatant was removed, and the
virus pellet was resuspended in Laemmli sample buffer prior to electrophoresis
through an SDS–12% polyacrylamide gel electrophoresis gel. The proteins were
electroblotted onto an Immobilon-P membrane (Millipore, Bedford, Mass.)
which was then blocked with 5% skim milk in phosphate-buffered saline–0.05%
Tween 20 (PBST). The blot was incubated overnight at 4°C in blocking solution
that contained the anti-HIV-1 Vpr-specific polyclonal antibody (NIH AIDS
Research and Reference Reagent Program) at a dilution of 1:2,000. Primary
antibodies were removed by washing the membranes three times for 30 min with
PBST at room temperature. The dilution of the secondary antibody and the
detection of Vpr were performed according to the protocol of the enhanced
chemiluminescence system (Amersham, Chicago, Ill.).
Vif functional assay. The Vif genes of LTNP 5 virus clones 2 and 3 were
isolated as XbaI-XhoI fragments using PCR and inserted into the HIV-1HXB-3
Vif expression vector pgVIF. Each Vif expression vector as well as the negative
control (pgDvif) was cotransfected into H9 cells with the vif-deficient proviral
vector pIIIB/Dvif. At 24 h posttransfection, viruses were harvested from the
culture supernatants, normalized according to reverse transcriptase activity, and
used in single-cycle infections of the indicator cell line C8166/HIV-CAT. After
an additional 30 h, the levels of chloramphenicol acetyltransferase (CAT) ex-
pression were measured from whole-cell lysates and used to determine relative
levels of infectivity. Whole-cell lysates of transfected H9 cultures were also
evaluated for Vif accumulation by Western blotting using a Vif-specific mono-
clonal antibody as previously described (51).
Experimental infection of rhesus monkeys. Virus diluted to contain 50 ng of
p27 antigen was inoculated intravenously into juvenile rhesus monkeys (Macaca
mulatta) (2). At various time points postinoculation, blood samples were col-
lected as previously described (15).
Determination of viral RNA and infectious cell loads. Cell-associated virus
loads in infected monkeys were determined by quantitative cocultivation of
PBMC with CEMx174 cells (12). PBMC were purified, counted in a hemocy-
tometer, and cocultured with CEMx174 cells in various numbers. On day 21, the
presence of SIV p27 antigen was determined and the numbers of PBMC needed
to recover SIV were calculated. The results described in this report represent
averages of duplicate determinations. Virion-associated SIV RNA in plasma
samples was quantified using a reverse transcription-PCR assay on an Applied
Biosystems Prism 7700 sequence detection system (Perkin-Elmer Cetus) (53).
Determination of the percentages of CD41 cells in blood of SHIVnef-infected
animals. Whole blood was drawn from SHIV nef-inoculated animals at various
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times postinoculation and stained with OKT4, a fluorescein isothiocyanate-con-
jugated murine monoclonal antibody that reacts with rhesus macaque CD4. The
stained samples were analyzed using a FACSscan flow cytometer (Becton Dick-
inson, San Jose, Calif.).
CCR5, CCR2, and SDF-1 genetic analysis. Genomic DNA was extracted from
patient samples using a DNA/RNA extraction kit (Amersham Life Science,
Piscataway, N.J.). CCR5, CCR2, and SDF-1 genetic polymorphisms were ampli-
fied using previously described oligonucleotides and procedures (11, 52, 57).
RESULTS
Introduction to patient population. The patients presented
here are HIV-1-infected individuals from the Massachusetts
area who have remained AIDS free with low viral loads with-
out antiretroviral intervention (Table 1). Seven of the eight
(LTNP 1, LTNP 2, LTNP 3, LTNP 5, LTNP 6, LTNP 7, and
161J) are individuals with hemophilia who were likely infected
by contaminated blood products. 1486D is a homosexual male.
Of the eight LTNPs, seven continue to be monitored for CD4
concentrations and viral load (Table 1) (17). LTNP 5 died in
June 1997 from complications of hepatitis C infection. At the
time of his last visit, LTNP 5 exhibited a CD4 concentration of
464/ml and maintained low but detectable viral RNA loads
(Table 1). In recent evaluations, CD4 concentrations from
LTNP 1 have declined although viral RNA loads remained
below the level of detection (Table 1) (19). This individual has
maintained a large deletion in Nef and 39 LTR sequences over
the entire course of infection, and no reversion of Nef se-
quence was observed during the period when CD4 concentra-
tions have declined (19, 27). Except for the recent treatment of
LTNP 1, none of the LTNPs in this report have received any
antiretroviral therapy for their HIV-1 infection despite infec-
tion in most cases for over 15 years (Table 1). 161J continues
to maintain detectable CD4 helper T-cell responses previously
shown to be associated with nonprogression (47). Detectable
proliferation responses to p24 antigen have been observed in
LTNPs 1, 2, and 3 but not in LTNPs 6 and 7 (17). LTNP 6 was
previously reported to contain a polymorphism in Sp1 binding
site III which resulted in suboptimal Tat-mediated transacti-
vation (28), consistent with the independent analysis described
in this report. LTNP 6 isolates were also shown to be defective
in a single cell killing assay in comparison to isolates from
progressors (44). LTNP 2, LTNP 3, and LTNP 6 Nef sequences
have been previously determined and were shown to be func-
tional in a CD4 down-regulation assay (38).
Analysis of HIV-1 second-receptor genotypes. Specific mu-
tations in the genes for HIV-1 second receptors CCR5 (D32)
and CCR2 (64I) and for the chemokine SDF-1 (39A) that is the
ligand for the CXCR4 second receptor have been associated
with slower progression to AIDS (11, 23, 30, 39, 49, 52, 57). We
investigated the extent to which these polymorphisms were
present in the eight LTNPs studied in this report. LTNP 5 and
LTNP 7 carried 1/D32CCR5 and 1/64ICCR2 protective geno-
types, respectively, and the other six patients contained more
common, nonprotective genotypes (Table 2). No patient was
homozygous for CCR5-D32, for CCR2-64I, or for SDF-1-39A
(Table 2).
HIV-1 sequences of LTNPs. Replication-competent HIV-1
was successfully isolated from seven of the eight LTNPs de-
scribed in this report by cocultivation of uninfected donor
PBMC with PBMC samples obtained in 1994 for LTNP 1,
TABLE 3. Summary of LTNP HIV-1 genotypic and
phenotypic characteristics
LTNP Virusisolationa
In vitro
growthb
Unusual
polymorphismsc
Frequency (%)
of polymorphism
in the databased
LTNP 1 Yes Good DNef (.100 aa) 0
LTNP 2 Yes Good None
LTNP 3 Yes Good D112p17gag 0
LTNP 5 Yes Poor D23TMenv 0
LTNP 6 Yes Good 4-base insertion
324U3LTR
0
4-aa insertion Vpu 4
D9-11TMenv 2
D49-50nef 9
1-aa deletion in Nef
C terminus
0
LTNP 7 Yes Good D466-467p6gag-pol 0
161J No NA D483-484p6gag-pol 0
D48-49Nef 0
1486D Yes Good D370p2gag 2
D465-466p6gag-pol 0
D48-49Nef 0
a For virus isolation LTNP PBMC were cocultivated with either bulk or CD8-
depleted, PHA-activated PBMC from seronegative donors.
b Good production of .100 ng of p24 antigen/ml in cocultivation assays. LTNP
5 isolates produced a maximum of 5 ng of p24 antigen/ml (poor growth). NA, not
applicable.
c Includes those that are difficult to revert and those that were consistently
observed in cultured virus and in patient PBMC.
d Frequency of polymorphism in the Los Alamos sequence database.
TABLE 1. Clinical history of LTNPs
LTNP
Date of first
seropositivity
detectiona
(mo-day-yr or yr)
Date of
last visitb
(mo-day-yr
or mo-yr)
Absolute
CD4 T-cell
counts/ml
at last visit
Plasma viral
RNA level at
last visit
(copies/ml)
LTNP 1 12-21-83 2-11-99 257c ,50
LTNP 2 3-7-84 9-16-98 589 58
LTNP 3 12-7-83 4-21-99 530 180
LTNP 5 2-1-84 3-2-95 464 644
LTNP 6 5-16-84 3-24-99 1,122 5,000
LTNP 7 2-29-84 1-6-99 606 97
161J 1979 6-15-99 843 ,50
1486D 1991 12-98 630 8,360
a LTNP 1, LTNP 2, LTNP 3, LTNP 6, and LTNP 7 were all seropositive at
their first visit. LTNP 5, 161J, and 1486D seroconverted between regularly
scheduled visits.
b The date shown is the date of the last visit. LTNP 5 died from complications
of hepatitis C infection in June 1997. All other patients are healthy as of their last
visit.
c CD4 T-cell counts in LTNP 1, who is infected with Nef-deleted HIV-1, began
declining around 1996 to 1997 despite consistently undetectable viral loads (19).
TABLE 2. LTNP CCR5, CCR2, and SDF-1 genotypesa
LTNP
Genotypeb of:
CCR5 CCR2 SDF-1
LTNP 1 1/1 1/1 1/39A
LTNP 2 1/1 1/1 1/1
LTNP 3 1/1 1/1 1/1
LTNP 5 1/D32 1/1 1/1
LTNP 6 1/1 1/1 1/1
LTNP 7 1/1 1/64I 1/39A
161J 1/1 1/1 1/39A
1486D 1/1 1/1 1/39A
a Patient samples were analyzed for HIV-1 second-receptor (CCR5 and
CCR2) and chemokine (SDF-1) polymorphisms associated with slower progres-
sion.
b 1, most common allele for each gene; D32, 64I, and 39A, CCR5, CCR2, and
SDF-1 polymorphisms, respectively, associated with slower 64I and 39A progres-
sion in the homozygous state; and D32 and 64I in the heterozygous state.
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LTNP 2, LTNP 3, LTNP 5, LTNP 6, and LTNP 7 as well as in
1995 for 1486D (Table 3) (17). DNA from cells infected with
these isolates served as the template for the amplification of
HIV-1 sequences. HIV-1 was not successfully isolated from
161J (Table 3); we used DNA from a PBMC sample obtained
in 1994 from 161J to serve as template for PCR.
The laboratories in which cellular DNA was purified and
HIV-1 sequences were amplified for this study are not other-
wise used for HIV-1 studies. All of the sequences from the
eight LTNPs described in this report were uniquely different
from one another and uniquely different from sequences of
laboratory strains of HIV-1 in the Los Alamos HIV-1 sequence
database (B. Korber, http://hiv-web.lanl.gov, Los Alamos Na-
tional Laboratory, 1999). Furthermore, as described below, the
examination of unusual HIV-1 polymorphisms in PBMC taken
at different times affirmed the authenticity of each sequence.
Thus, the sequences reported here are authentic and cannot be
due to contamination.
All eight LTNPs described here lived, and were likely in-
fected, in the United States, where group M, subtype B, iso-
lates vastly predominate. Full-length sequences from all eight
LTNPs were analyzed using the Los Alamos subtyping pro-
gram and subtype reference sequences (B. Korber, www.ncbi
.nih.gov). Nucleotide sequences of all eight LTNPs had the
highest relatedness to subgroup B sequences across the entire
length of the HIV-1 genome. The relatedness of 1486D
sequences to sequences of different subgroups is shown as
an example in Fig. 1. In addition, dendrograms based on
alignments of LTNP Gag and Nef amino acid sequences were
generated (Fig. 2). Neighbor-joining analyses demonstrated
that the LTNP Gag (Fig. 2A) (confidence value of 99) and Nef
sequences (Fig. 2B) (confidence value of 77) were most closely
related to subgroup B sequences. Trees using parsimony anal-
ysis revealed identical intersubtype relationships among the
LTNP and reference Gag and Nef sequences.
Analysis of Gag sequences revealed that five of the eight
LTNPs contained 1- or 2-amino-acid (aa) deletions in Gag
compared to subgroup B consensus sequences (Fig. 3B and
Table 3). HIV-1 from LTNP 3 had a deletion in p17gag
(1 aa); HIV-1 from LTNP 1 had a deletion in p2gag (1 aa);
HIV-1 from LTNP 7 had a deletion in the p6gag-pol overlap
region (2 aa); HIV-1 from 1486D had deletions in both p2gag
(1 aa) and p6gag-pol (2 aa); and 161J had two separate dele-
tions in p6gag-pol (1 and 2 aa) (Fig. 3B and Table 3). None of
the Gag deletions were independently observed in different
subjects. To ensure that these deletions were representative
of sequences maintained in these subjects, DNA was iso-
lated from LTNP PBMC obtained at distinct times and used
as the template for PCR. These experiments revealed that
the polymorphisms in Gag sequences described here were
consistently observed for PBMC samples obtained in 1985
and 1994 for LTNP 3, 1983 and 1994 for LTNP 1 and LTNP 7,
FIG. 1. Subtyping of the HIV-1 sequence of LTNP 1486D. 1486D sequences from bp 297 to 9607 (numbers based on NL 4-3 sequences) were analyzed using the
Los Alamos subtyping program and subtyping reference sequences. The score value indicates the relative relatedness of 1486D sequences at different loci throughout
the genome. The color of the bar at the top indicates the subtype that 1486D sequences are most closely related to at loci throughout the HIV-1 genome.
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1992 and 1995 for 1486D, and 1994 and 1998 for 161J (data not
shown). The Los Alamos HIV-1 sequence database (B. Korber,
http://hiv-web.lanl.gov) containing Gag sequences from 93
group M, group O, and SIVcpz isolates was examined for the
Gag polymorphisms observed in our LTNP sequences. The
p17gag D112 polymorphism contained in HIV-1 from LTNP 3
was not observed in any of the isolates in the database. The
2-aa p6gag polymorphisms contained in HIV-1 from 161J
(D483-484), LTNP 7 (D466-467), and 1486D (D465-466) were
also not observed in any of the isolates in the database, al-
though D467 was observed for four subgroup A sequences (B.
Korber, http://hiv-web.lanl.gov). The p2gag D370 polymorphism
contained in HIV-1 from 1486D was observed in two database
sequences: one from subgroup B (GA.OYI) and one from
subgroup F (FI.FIN9363). We independently derived Gag se-
quences from four Massachusetts subjects who had progressed
to AIDS. In contrast to what was observed in the LTNP Gag
sequences, we observed no unusual polymorphisms in the Gag
sequences from these four progressors (data not shown). In
addition, we scanned 90 group M Gag sequences in the Los
Alamos database and did not find a single example of a dele-
tion unique to a single individual. Thus, the polymorphisms
observed in four of the LTNPs are unique among determined
HIV-1 Gag sequences and their occurrence appears to be non-
random in nature.
In addition to the Gag deletions, small deletions and inser-
tions were also observed in other LTNP HIV-1 sequences that
have not previously been seen in any subgroup B sequence in
the database (B. Korber, http://hiv-web.lanl.gov). LTNP 5 con-
tained a single amino acid deletion in the transmembrane (gp
41) protein encoded by the env gene (Fig. 3E and Table 3).
This mutation was consistently contained in PBMC samples
obtained from LTNP 5 in 1987 and 1994 and was not observed
in the sequences of the 131 isolates in the Los Alamos HIV-1
sequence database (B. Korber, http://hiv-web.lanl.gov). LTNP
6 HIV-1 cultures from virus obtained in 1984 and 1995 had a
3-aa deletion in gp41 that was previously observed in only
three subgroup C isolates (C.DJ.DJ259A, C.DJ.DJ373A, and
C.ET.ETH2220). Cultured virus from LTNP 6 from 1984 and
1995 also retained a 4-bp insertion in nef and 39-LTR se-
quences (Fig. 3A) that resulted in truncation of LTNP 6 Nef
by 1 aa short of the consensus C-terminal cysteine (Fig. 3J).
This polymorphism has not been previously noted in any of the
256 Nef sequences in the Los Alamos HIV-1 sequence data-
base (B. Korber, http://hiv-web.lanl.gov). HIV-1 from LTNP 6
obtained in 1984 and 1995 also had a 2-aa deletion in Nef
(D49-50; Fig. 3J and Table 3) which appears in about 9% of
subgroup B Nef sequences and represents the consensus for
subgroup E Nef. LTNP 6 isolates also contained a 4-aa inser-
tion near the N terminus of Vpu (Fig. 3G; Table 3) which is
similar to a 4-aa insertion contained in four subgroup B iso-
lates in the database. The 4 aa insertion was not detected in
LTNP 6 PBMC samples obtained in 1984 but was detected in
samples obtained in 1987 and at later times (Fig. 4). Cultured
LTNP 1 virus maintained a large deletion in the 39-LTR and
Nef sequences (Fig. 3A and Table 3), similar to what has been
FIG. 2. Dendrograms of reference sequences of HIV-1 isolates of different subtypes and LTNP sequences for Gag (A) and Nef (B). These analyses were performed
using PAUP. Bootstrap confidence values were assigned when a minimum value of 70 was achieved for a particular branch. The dendrogram was rooted to the
SIVcpzGAB sequences. The identification of the subtype isolates which are symbolized here is described in Material and Methods.
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observed previously (27). The PBMC sample obtained from
161J in 1994 revealed a 2-aa deletion in Nef (D48-49) (Fig. 3J
and Table 3) that was also retained in PBMC obtained in 1998
from 161J. Cultured 1486D HIV-1 from 1995 maintained
D48-49 Nef and also maintained a 1-aa insertion in Nef (61Q;
Fig. 3J and Table 3). These polymorphisms were retained in
1486D 1995 PBMC (Fig. 5). However, the 61Q insertion was
not observed in 1486D 1992 PBMC, suggesting that the addi-
FIG. 3. Alignments of LTNP sequences. Nucleotide (A) and amino acid (B to J) sequences of the indicated HIV-1 genetic elements and proteins were aligned to
the group M, subgroup B, consensus sequences (HIV-1). Periods indicate conservation between LTNP and consensus B sequences. A dash indicates that a base or
amino acid is not contained in a particular sequence. Unusual polymorphisms consistently observed in HIV-1 sequences from LTNPs are highlighted in black. The data
presented represent consensus sequences from two clones from each of two independent PCRs.
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tion of this amino acid took place in the intervening period
(1992 to 1995) between samplings. As described above, D49-50
is maintained in about 9% of subgroup B isolates and repre-
sents the subgroup E Nef consensus sequence. However,
D48-49 and the 61Q insertion have not been previously ob-
served (B. Korber, http://hiv-web.lanl.gov).
HLA haplotypes. Specific sequences in Gag and Nef serve as
MHC-I-restricted epitopes for CTL recognition (20, 31, 34).
Sequence variations in these proteins can result in escape from
CTL recognition. Six of the eight LTNPs described here had
deletions in Gag and/or Nef. In many cases, these deletions
were located in close proximity to each other: 1486D p2gag
D370 versus LTNP 1 p2gag D373, 1486D p6gag D465-466 versus
LTNP 7 p6gag D466-467 and 161J p6gag D471, and 1486D and
161J D48-49 Nef versus LTNP 6 D49-50 Nef (Fig. 3 and Table
4). We investigated whether common HLA types correlated
with clustered polymorphisms among the LTNPs. 1486D and
LTNP 1 shared the HLA C6 allele in addition to p2gag dele-
tions that were only 3 aa apart (Fig. 3B and Table 4). Con-
versely, 1486D, LTNP 7, and 161J, who had p6gag deletions at
similar locations, did not have any common HLA alleles. Sim-
ilarly, 1486D, 161J, and LTNP 6, who had Nef deletions at
similar locations, also did not have any common HLA alleles
(Table 4).
Incorporation of HIV-1 Vpr by LTNP p6gag. p6gag facilitates
the incorporation of Vpr into HIV-1 particles (29, 37). Three
of the eight LTNPs in this study harbored HIV-1 that had
deletions in p6gag. We tested the ability of LTNP p6gag se-
quences to facilitate the incorporation of Vpr into recombinant
HIV-1. ApaI-BclI restriction fragments derived from amplified
LTNP sequences were inserted into p83-2, a vector which
contained 59 half sequences of the HIV-1 strain NL 4-3 (1).
Recombinant virus containing 500 ng of p24 as well as NL 4-3
and DVpr controls were subjected to SDS-PAGE and assayed
for Vpr incorporation by Western blotting with polyclonal anti-
Vpr sera (Fig. 6). A Vpr-specific band was detected from puri-
fied NL 4-3 (Fig. 6, lane 1) that was not detected from purified
DVpr virus (Fig. 6, lane 2). A Vpr-specific band was also detect-
ed from all eight purified recombinant viruses that expressed
LTNP p6gag sequences at levels similar to that of the NL 4-3
control (Fig. 6, lanes 3 to 10). Thus, all LTNPs contained p6gag
sequences that facilitated the efficient incorporation of Vpr
into virions.
Infection of monkeys with SHIVnef containing 1486D Nef
sequences. We have previously demonstrated that HIV-1 Nef
can substitute for SIVmac Nef in vivo to produce a pathogenic
infection in rhesus monkeys (2). 1486D Nef sequences isolated
in 1992 (D48-49) and 1995 (D48-49 and insertion 61Q; Fig.
5) were evaluated for their performance in rhesus monkeys
in the context of SHIVnef. We created SHIVnef recombi-
nants by engineering the corresponding nef sequences into
SIVDnefXESAB, resulting in SHIVnef-1486D92 and SHIVnef-
1486D95, respectively. Two juvenile rhesus monkeys were in-
oculated intravenously with either SHIVnef-1486D92 (Mm
32-97 and Mm 33-97) or SHIVnef-1486D95 (Mm 34-97 and
Mm 35-97) containing 50 ng of p27 antigen. We monitored
FIG. 3—Continued.
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FIG. 3—Continued.
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plasma antigenemia, CD4 counts, numbers of infectious cells
in PBMC, and viral RNA loads with blood samples obtained at
intervals following experimental infection of these monkeys.
These analyses revealed that Mm 32-97 and Mm 33-97 did not
maintain consistently measurable numbers of infectious cells in
PBMC or RNA loads in a readily measurable range (Fig. 7C
and D). Conversely, Mm 34-97 and Mm 35-97 displayed per-
sistently high numbers of infectious cells in PBMC and high
RNA loads. We investigated if Nef sequences in Mm 32-97 and
Mm 33-97 were under selective pressure to acquire the 61Q
insertion. At week 44 postinoculation we did not observe this
polymorphism in Mm 32-97 and Mm 33-97. The 61Q polymor-
phism was retained in Mm 34-97 and Mm 35-97 at the same
time point (Fig. 5). We also examined if the D48-49 deletion
was stable in the 1486D Nef sequences and found that this
polymorphism had been maintained in all four animals at 44
weeks postinoculation (Fig. 5).
Determinants for poor growth of HIV-1 from LTNP 5. Of
the seven LTNP HIV-1 isolates that were successfully cultured,
six grew well in infected PBMC cultures (Table 3). Only LTNP
5 HIV-1 grew poorly (Table 3), reaching a maximum p24
concentration of 5 ng/ml in PBMC obtained from several se-
ronegative donors (17). We investigated potential determi-
nants of this slow- or low-growth phenotype. Chimeric LTNP
5/NL 4-3 HIV-1 was created to assess the effect of LTR, Gag,
and Pol sequences on LTNP 5 replication. LTNP 5 and NL 4-3
sequences from bp 297 to 4402 (59) and NL 4-3 sequences from
bp 4402 to 9607 (39) (Fig. 3) were amplified separately. An
XmaI (CCCGGG) site was introduced at the junction of the
PCR fragments (bp 4402) as described in Materials and Meth-
ods. XmaI-digested 59 LTNP 5 and 59 NL 4-3 fragments
were cotransfected with 39 NL 4-3 fragments into permissive
CEMx174 cells. Supernatants were collected starting at day 3
posttransfection and assayed for p27 antigen concentration.
Production of both wild-type NL 4-3 and recombinant 59
LTNP 5–39 NL 4-3 peaked at day 9 posttransfection with sim-
ilar peak yields (Fig. 8). Thus, the 59 sequences in LTNP 5 to
bp 4402 seem suitably competent for viral replication.
Previous studies have shown that vpu, vpr, and nef can be
deleted from HIV-1 with little or no effect on replication in
lectin-stimulated PBMC cultures (16, 26). Therefore, vpu, vpr,
and nef are unlikely to be responsible for the poor growth of
HIV-1 from LTNP 5. Among additional LTNP 5 sequences
contained in the 39 LTNP 5 sequences that could contribute to
slow growth, no unusual, difficult-to-revert mutations were ob-
served in integrase, vif, tat, rev, and U3 LTR sequences (Fig. 3
and Table 3). Among these sequences, LTNP 5 vif sequences
displayed the greatest divergence from the subgroup B con-
sensus as well as from the LTNP vif sequences presented here
(Fig. 1D). LTNP 5 vif allele 2 and LTNP 5 vif allele sequences
as well as HBX-3 vif-positive control sequences were inserted
into an expression vector and were cotransfected with a vif-
deficient proviral vector pIIIB/Dvif into H9 cells. Western blots
of whole-cell lysates from transfected H9 cultures indicated
that the vectors containing LTNP 5 vif alleles 2 and 3 and
HBX-3 vif sequences expressed comparable levels of Vif
(Fig. 10B). HIV-1 produced from these cells was used in
single-cycle challenges of the indicator cell line C8166/HIV-
CAT to assess Vif function. Cells transfected with LTNP 5
vif alleles 2 and 3 and HXB-3 vif produced similar levels of
CAT (Fig. 10A) in this assay, indicative of the wild-type-like
activity of these LTNP 5 vif genes.
Our analysis of LTNP 5 isolate sequences revealed a diffi-
cult-to-revert polymorphism in LTNP 5 env sequences (Fig. 3E
and Table 3) that was also contained in the 39 LTNP 5 PCR
fragments. A single amino acid deletion in the fusion peptide
region of the transmembrane domain (Fig. 3E and Table 3)
was consistently retained in LTNP 5 virus isolates and in
PBMC samples obtained in 1987 and 1994. This polymorphism
is not observed in any of the 131 group M, group O, or SIVcpz
Env sequences in the Los Alamos database (B. Korberg, http:
//hiv-web.lanl.gov) and represents the only deletion or in-
sertion contained in LTNP 5 HIV-1 sequences (Fig. 3 and
Table 3).
DISCUSSION
HIV-1 gene sequences from LTNPs have been investigated
extensively in order to determine if inactivating polymorphisms
are associated with nonprogression. Nucleotide and amino
acid substitutions have been associated with defective p17 and
Rev activities (5, 25). Among the auxiliary genes, several ex-
amples of large deletions in nef have been documented (10, 27)
but have not been observed in LTNP vpu or vpr sequences.
Thus, the types of polymorphisms described here are unusual
in that they are difficult to revert and in many cases without
precedent in the Los Alamos HIV-1 sequence data base (B.
Korber, http://hiv-web.lanl.gov).
Seven of the eight LTNPs contained a total of 13 unusual,
difficult-to-revert polymorphisms in HIV-1 sequences. The rate of
misincorporation during the process of reverse transcription
has been estimated at approximately 3 3 1024 bases or
approximately one misincorporation per genome transcribed
(4, 40, 46). Amino acid polymorphisms that are detrimental to
FIG. 3—Continued.
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the virus rapidly revert (26, 32). Conversely, the elimination of
insertion or deletion polymorphisms requires slippage or stut-
tering of reverse transcriptase, which is a much rarer occur-
rence. A 4-aa deletion in SIV Nef has been repaired by dupli-
cation of adjacent sequences and subsequent reversion to wild-
type sequences (56). However, reversion of this deletion is rare
and is not observed in most infected monkeys. In all cases
presented here, with the exception of the 4-aa insertion in
FIG. 3—Continued.
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LTNP 6 Vpu, difficult-to-revert polymorphisms were consis-
tently present in historical samples from the LTNPs.
Five of the eight LTNPs in this study had deletions of 1 or 2
aa in p17gag, p2gag, and/or p6gag (Fig. 3B and Table 3). Four had
deletions that did not appear in 93 group M, group O, or
SIVcpz isolates in the Los Alamos HIV-1 sequence database
(B. Korber, http://hiv-web.lanl.gov). In contrast, we did not
observe any difficult-to-revert polymorphisms in the Gag se-
FIG. 4. Alignment of LTNP 6 Vpu sequences. LTNP 6 amino acid sequences from the time points indicated (e.g., P84, PBMC sample obtained in 1984) were aligned
to the group M, subgroup B, consensus sequences (HIV-1). V, sequences were obtained from isolated HIV-1. Each sequence represents a consensus of two clones from
each of two independent PCRs. Periods indicate conservation between LTNP 6 and the consensus B sequences. A dash indicates that an amino acid is not contained
in a particular sequence. The 4-aa insertion observed in Vpu sequences from LTNP 6 is highlighted in black.
FIG. 3—Continued.
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quences isolated from four individuals that progressed to
AIDS and we did not observe a single example of a unique
deletion in Gag among 90 group M sequences in the Los
Alamos database. These results suggest that the deletions in
Gag that we observed occurred in a nonrandom fashion in our
group of LTNPs. HIV-1 isolated from the LTNPs containing
these polymorphisms was able to replicate in culture (Table 3)
(17), indicating that they do not dramatically debilitate the
virus. However, they could possibly have subtle effects on Gag
function that may lower replicative capacity or result in atten-
uation. Three of the four unique Gag deletions occurred in p6
sequences (161J D483-484, LTNP 7 D466-467, and 1486D
D465-466). Vpr incorporation into virions was not detectably
affected by the p6 deletions (Fig. 6).
The Nef sequences from the LTNPs belonged to group M,
subgroup B (Fig. 2), as would be expected since these individ-
uals live and were likely infected in the United States where
subgroup B sequences predominate. The polymorphism seen
in Nef sequences isolated from LTNP 6 (D49-50) (Fig. 3J) is
found in about 9% of subgroup B sequences although it rep-
resents the subgroup E consensus, which is predominant in
Asia. Conversely, the Nef polymorphism (D48-49) observed in
161J and 1486D isolates (Fig. 3J) was not observed in any of
the 256 Nef sequences in the Los Alamos HIV-1 sequence
database (B. Korber, http://hiv-web.lanl.gov). Monkeys in-
fected with SHIVnef that contained 1486D sequences from
1992 (D48-49) maintained low viral loads in contrast to mon-
keys infected with 1486D sequences from 1995 (D48-49 and
61Q insertion), which maintained persistently high viral loads
(Fig. 7). These results are consistent with 1486D 1992 Nef
sequences being less than optimal for Nef function and with
the 61Q insertion resulting in a more functional Nef. However,
these results are based on only four animal infections and are
not statistically significant (2).
The extreme slow/low growth phenotype observed for HIV-1
isolates from LTNP 5 (17) appears to map to the env region.
LTNP 5 Env contains a polymorphism in the fusion peptide
region of gp41 which was not observed in any of the 131
isolates in the Los Alamos HIV-1 sequence database
(B. Korber, http://hiv-web.lanl.gov). The fusion peptide of
gp41 inserts into target cell membranes, which is critical to the
fusion process between cellular and viral membranes (7). The
LTNP 5 Env polymorphism could affect this or other Env
functions, resulting in the observed slow/low growth pheno-
type. Sequences responsible for a slow/low growth phenotype
in other isolates have previously been mapped to Env amino
acid substitutions in the V3 and C2-V4 regions (9, 24, 42, 50,
55) and thus could easily revert. The polymorphism seen in
LTNP 5 Env is not an amino acid substitution, is maintained
through long-term passage in cell culture, and is not likely to
revert easily to a more rapid/high phenotype.
The origins of the unusual, difficult-to-revert polymorphisms
observed in seven of our eight patients cannot be definitively
determined with the samples available. As was clearly the case
with eight Australians infected with Nef-deleted HIV-1 from a
single blood donor (33), it is possible that many of the poly-
morphisms in our seven subjects were present in the infecting
inoculum. Since the noted polymorphisms would be difficult to
revert, they could have long-term attenuating effects on the
virus. Alternatively, the unusual polymorphisms could have
arisen in the infected hosts in response to selective pressures.
Two types of selective pressures can be envisioned: the host
immune response and polymorphisms in host cell proteins that
FIG. 6. LTNP p6gag-mediated Vpr incorporation. Recombinant HIV-1 con-
taining LTNP p6gag sequences were purified by centrifugation. Virally associated
proteins were separated by SDS-PAGE and electroblotted onto a membrane
filter. HIV-1 Vpr was detected using a Vpr-specific polyclonal antiserum. Lane 1,
NL 4-3 parental virus; lane 2, NL 4-3DVpr; lanes 3 to 10, recombinant HIV-1
containing LTNP p6gag sequences: lane 3, LTNP 2; lane 4, LTNP 1; lane 5, LTNP
3; lane 6, LTNP 5; lane 7, LTNP 6; lane 8, LTNP 7; lane 9, 161J; lane 10, 1486D.
FIG. 5. Amino acid sequences of 1486D Nef after infection into rhesus monkeys with SHIVnef recombinants. A SHIVnef recombinant containing 1486D Nef
sequences from PBMC obtained in 1992 (P92) was inoculated into Mm 32-97 and Mm 33-97, and a recombinant containing 1486D Nef sequences obtained in 1995
was inoculated into Mm 34-97 and Mm 35-97. The sequences in the inoculum and sequences obtained from the infected animal 44 weeks postinoculation were aligned
to the group M, subgroup B, consensus (HIV-1) sequences. Each sequence represents a consensus of two clones from each of two independent PCRs. Periods indicate
conservation between 1486D and the consensus B sequences. A dash indicates that an amino acid is not contained in a particular sequence. The deletion and insertion
polymorphisms observed in Nef sequences from 1486D are highlighted in black.
TABLE 4. Comparison of LTNP Gag and Nef deletions
and HLA types
LTNP Gag deletionsa Nef deletionsa HLA typeb
LTNP 1 373 .100 aa A2, B13, B62, C2, C5
LTNP 2 112 None A2, B44, C2, C5
LTNP 6 None 49–50 A1, A2, B44, B57, C5, C6
LTNP 7 466–467 None A3, A31, B38, B64, C5, C12
161J 471, 483–484 48–49 A2, A3, B7, B60, C3
1486D 370, 465–466 48–49 A1, A24, B57, B65, C4, C6
a Amino acid(s) consistently absent in LTNP sequences.
b Designation of a single A, B, or C allele indicates that a patient is homozy-
gous at that locus.
4372 ALEXANDER ET AL. J. VIROL.
 o
n
 January 13, 2016 by NO
VA SO
UTHEASTERN UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
must partner with HIV-1 proteins. With respect to selective
pressures from host immune responses, strong CTL re-
sponses have been measured in all eight of these LTNPs.
These strong cellular responses could put significant pres-
sure on the virus to escape immune surveillance. However,
deletions and insertions within ordinarily conserved sequences
would be an unusual way for the virus to avoid immune rec-
ognition and would not be obviously advantageous over simple
point mutations. Furthermore, we did not observe any consis-
tent pattern of MHC-I haplotypes associated with similarly
located deletions in the HIV-1 sequence. MHC-II-restricted
CD4 helper cell activity could also conceivably be a selective
force for driving sequence changes in the virus. With respect to
possible polymorphisms in host cell proteins that must partner
HIV-1 proteins, it is curious to note that heterozygosity for the
SDF-1-39A polymorphism seemed to be associated with simi-
larly located Gag and Nef deletions in 1486D, 161J, and LTNP
7.
For the LTNPs in this study, we did not observe homozygous
polymorphisms in second-receptor or chemokine genes (Table
2) that have been previously documented to be associated with
nonprogression (11, 23, 39, 52, 57). We have observed unusual,
difficult-to-revert polymorphisms in HIV-1 sequences from
LTNPs that were not observed in the evaluated sequences
from individuals who progressed to AIDS. Furthermore, most
of these unusual polymorphisms are without precedent among
observed HIV-1 sequences. Although we have not directly
demonstrated that these deletions have contributed to their
rate of disease progression, they appear to be associated with
the unusual clinical status of these individuals in an apparently
nonrandom fashion. Additional studies using monkeys and
SIV or SHIV recombinants with deletions analogous to those
observed in the LTNPs will be required to document any
contribution to lowering viral load or attenuation of disease
progression.
FIG. 8. Growth of recombinant HIV-1 containing 59 LTNP 5 sequences.
LTNP 5 and NL 4-3 sequences from bp 297 to 4402 (59) and NL 4-3 sequences
from bp 4402 to 9607 (39) were amplified separately. An XmaI (CCCGGG) site
was introduced at the junction of the PCR fragments (bp 4402) as described in
Materials and Methods. XmaI-digested 59 LTNP 5 and 59 NL 4-3 fragments were
cotransfected with 39 NL 4-3 fragments into permissive CEMx174 cells. Super-
natants were collected and assayed for p27 antigen concentration.
FIG. 7. Plasma antigenemia, CD4 percentage, PBMC load, and RNA copy (equivalents per milliliter) measurements for animals infected with SHIVnef recom-
binants containing 1486D Nef sequences. (A) Plasma antigenemia in SHIVnef-infected rhesus monkeys. p27 concentrations in plasma were determined at the time
points indicated. The limit of detection is approximately 0.05 ng/ml. The week 0 sample is a preinfection sample taken immediately before inoculation with SHIVnef.
(B) CD4 percentages in SHIVnef-infected rhesus monkeys. Whole blood was drawn from SHIVnef-inoculated animals at various times postinoculation and stained with
OKT4, a fluorescein isothiocyanate-conjugated murine monoclonal antibody that was raised against rhesus macaque CD4 (American Type Culture Collection). The
stained samples were analyzed using a FACSscan flow cytometer (Becton Dickinson). (C) Frequencies of infectious cells in PBMC of SHIVnef-infected rhesus
macaques. Viral loads were graded on a scale from 0 to 10 indicating the number of PBMC needed to recover SIV. A value of 0 denotes that no virus was recovered
using 106 cells, 1 denotes successful virus recovery from 106 cells, and 2 to 10 denote successful virus recovery from 333,333, 111,111, 37,037, 12,345, 4,115, 1,371, 457,
152, or 51 cells, respectively. (D) Plasma SIV RNA levels at the indicated weeks postinoculation for animals infected with SHIVnef recombinants. The dashed line
indicates the threshold sensitivity of the assay, 300 copy eq/ml. A value of 0 was assumed for week 0.
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